Human Serum Amyloid a Impaired Structural Stability of High-Density Lipoproteins (HDL) and Apolipoprotein (Apo) A-I and Exacerbated Glycation Susceptibility of ApoA-I and HDL.

apolipoprotein A-I glycation human serum amyloid A oxidation reconstituted high-density lipoprotein

Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
01 Jul 2022
Historique:
received: 18 05 2022
revised: 24 06 2022
accepted: 30 06 2022
entrez: 9 7 2022
pubmed: 10 7 2022
medline: 14 7 2022
Statut: epublish

Résumé

Human serum amyloid A (SAA) is an exchangeable apolipoprotein (apo) in high-density lipoprotein (HDL) that influences HDL quality and functionality, particularly in the acute phase of inflammation. On the other hand, the structural and functional correlations of HDL containing SAA and apoA-I have not been reported. The current study was designed to compare the change in HDL quality with increasing SAA content in the lipid-free and lipid-bound states in reconstituted HDL (rHDL). The expressed recombinant human SAA1 (13 kDa) was purified to at least 98% and characterized in the lipid-free and lipid-bound states with apoA-I. The dimyristoyl phosphatidylcholine (DMPC) binding ability of apoA-I was impaired severely by the addition of SAA, while SAA alone could not bind with DMPC. The recombinant human SAA1 was incorporated into the rHDL (molar ratio 95:5:1, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC): cholesterol: apoA-I) with various apoA-I:SAA molar ratios from 1:0 to 1:0.5, 1:1 and 1:2. With increasing SAA1 content, the rHDL particle size was reduced from 98 Å to 93 Å, and the α-helicity of apoA-I:SAA was decreased from 73% to 40% for (1:0) and (1:2), respectively. The wavelength maximum fluorescence (WMF) of tryptophan in rHDL was red-shifted from 339 nm to 345 nm for (1:0) and (1:2) of apoA-I:SAA, respectively, indicating that the addition of SAA to rHDL destabilized the secondary structure of apoA-I. Upon denaturation by urea treatment from 0 M to 8 M, SAA showed only a 3 nm red-shift in WMF, while apoA-I showed a 16 nm red-shift in WMF, indicating that SAA is resistant to denaturation and apoA-I had higher conformational flexibility than SAA. The glycation reaction of apoA-I in the presence of fructose was accelerated up to 1.8-fold by adding SAA in a dose-dependent manner than that of apoA-I alone. In conclusion, the incorporation of SAA in rHDL impaired the structural stability of apoA-I and exacerbated glycation of HDL and apoA-I.

Identifiants

pubmed: 35807498
pii: molecules27134255
doi: 10.3390/molecules27134255
pmc: PMC9268363
pii:
doi:

Substances chimiques

Apolipoprotein A-I 0
Lipoproteins, HDL 0
Serum Amyloid A Protein 0
Cholesterol 97C5T2UQ7J
Dimyristoylphosphatidylcholine U86ZGC74V5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Gerontol A Biol Sci Med Sci. 2010 Jun;65(6):600-10
pubmed: 20421239
Biochim Biophys Acta. 2014 Oct;1842(10):1467-74
pubmed: 25063355
Biochemistry. 1979 Feb 20;18(4):574-9
pubmed: 217418
Amyloid. 2012 Mar;19(1):5-14
pubmed: 22320226
Biochem J. 1988 Dec 15;256(3):775-83
pubmed: 3223951
Int J Mol Sci. 2022 Apr 02;23(7):
pubmed: 35409326
FEBS Open Bio. 2015 Apr 07;5:276-82
pubmed: 25893163
Rejuvenation Res. 2012 Jun;15(3):313-21
pubmed: 22530728
Sci Rep. 2021 Mar 30;11(1):7217
pubmed: 33785815
J Lipid Res. 2005 Mar;46(3):589-96
pubmed: 15716588
Biomolecules. 2021 Dec 15;11(12):
pubmed: 34944527
J Clin Lipidol. 2021 Nov-Dec;15(6):796-804
pubmed: 34802985
Proc Natl Acad Sci U S A. 1977 Sep;74(9):4025-8
pubmed: 198813
Biochem Cell Biol. 2016 Aug;94(4):337-45
pubmed: 27487295
J Lipid Res. 2001 Mar;42(3):379-89
pubmed: 11254750
Gene. 2016 May 25;583(1):48-57
pubmed: 26945629
Anal Biochem. 1978 Jun 15;87(1):206-10
pubmed: 98070
FEBS Lett. 2008 Mar 5;582(5):579-85
pubmed: 18243142
J Biol Chem. 1987 Jul 25;262(21):10035-8
pubmed: 3611052
Circulation. 2004 Feb 17;109(6):726-32
pubmed: 14970107
Eur J Clin Invest. 2019 Feb 27;:e13095
pubmed: 30810222
J Lipid Res. 2015 Aug;56(8):1531-42
pubmed: 26022803
Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):763-72
pubmed: 10712402
Biochemistry. 1972 Oct 24;11(22):4120-31
pubmed: 4343790
Eur J Clin Invest. 1996 Jun;26(6):427-35
pubmed: 8817153
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1890-1900
pubmed: 29976766
Lipids Health Dis. 2020 Sep 7;19(1):204
pubmed: 32892746
Biochem Biophys Res Commun. 2010 Feb 12;392(3):295-300
pubmed: 20059975
PLoS One. 2016 Oct 13;11(10):e0164564
pubmed: 27736980
Curr Opin Lipidol. 2020 Oct;31(5):300-301
pubmed: 32881753
J Biol Chem. 1986 Jul 25;261(21):9644-51
pubmed: 3525531
J Clin Invest. 1955 Sep;34(9):1345-53
pubmed: 13252080
Front Cell Dev Biol. 2022 Jan 05;9:795460
pubmed: 35071235
J Biol Chem. 2000 Sep 1;275(35):26821-7
pubmed: 10858436
J Infect. 2020 Jun;80(6):646-655
pubmed: 32277967
FEBS Lett. 2016 Mar;590(6):866-79
pubmed: 26918388
J Clin Invest. 1972 Oct;51(10):2773-6
pubmed: 5056669
J Lipid Res. 2020 Mar;61(3):328-337
pubmed: 31915139
Mediators Inflamm. 2014;2014:793628
pubmed: 25525305
Arterioscler Thromb Vasc Biol. 2011 Jun;31(6):1326-32
pubmed: 21474830
Molecules. 2021 Dec 10;26(24):
pubmed: 34946565
Molecules. 2021 Jul 16;26(14):
pubmed: 34299592
Biochemistry. 1988 Mar 22;27(6):1901-7
pubmed: 3132203
Sci Rep. 2017 Nov 21;7(1):15886
pubmed: 29162870
Antioxidants (Basel). 2021 Feb 01;10(2):
pubmed: 33535459
Curr Atheroscler Rep. 2021 Jan 15;23(2):7
pubmed: 33447953
Proc Natl Acad Sci U S A. 1975 Apr;72(4):1473-6
pubmed: 805429
Mol Cells. 2009 Mar 31;27(3):291-7
pubmed: 19326075
Biochim Biophys Acta Mol Basis Dis. 2017 Jan;1863(1):200-210
pubmed: 27768903
Methods Enzymol. 1986;128:223-46
pubmed: 3088390
J Lipid Res. 2021;62:100067
pubmed: 33741421

Auteurs

Kyung-Hyun Cho (KH)

LipoLab, Yeungnam University, Gyeongsan 38541, Korea.
Raydel Research Institute, Medical Innovation Complex, Daegu 41061, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH